Via practica 4/2025
Telmistar III Study: Efficacy and safety of hypertension therapy with telmisartan and SPC telmisartan/ amlodipine and their effect on blood pressure variability in the hypertensive patients in Slovakia
Arterial hypertension is among the leading causes of morbidity and mortality both in Slovakia and globally. Early and effective treatment of arterial hypertension slows the progression of target organ damage, reduces hospitalization rates, and lowers cardiovascular mortality. Recent observations suggest that optimal reduction of cardiovascular diseases requires not only achieving target blood pressure (BP) levels but also reducing BP variability and ensuring a consistent 24-hour BP reduction. The observational Telmistar III study evaluated the efficacy and safety of telmisartan (T) and SPC telmisartan/amlodipine (T/A) in 393 hypertensive patients in Slovakia. Treatment with both T and T/A led to a significant BP reduction, decreased BP variability, and favorable effects on 24-hour ambulatory blood pressure monitoring (ABPM) parameters, including the smoothness index. The treatment was well tolerated, with high patient and physician satisfaction. The Telmistar III study confirmed that telmisartan and its SPC with amlodipine represent effective and safe antihypertensive therapy with a positive impact on BP and its variability.
Keywords: hypertension, telmisartan, telmisartan/amlodipine SPC (single-pill combination), ambulatory blood pressure monitoring, blood pressure variability, Telmistar III
